Category: Interpretational.com

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care — — Overall, Treatment with Veklury Resulted in Five Days Faster Recovery and Reduced Disease Progression Compared with Placebo — — Veklury Reduced Mortality by 70 Percent at Day 29 in Patients on Low-Flow Oxygen at Baseline in Post-Hoc Analysis...

Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients With Advanced Prostate Cancer

81% Reduction in the Risk of Radiographic Progression or Death, Hazard Ratio=0.19 (p Medivation to Hold Conference Call at 8:30 a.m. Eastern Time Today San Francisco, CA and Tokyo – October 22, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the Independent Data Monitoring Committee (IDMC) has informed the companies of positive results...

Consumer Confidence stalls at zero

Do Brexit jitters explain 18-point fall since March 2015 in sentiment over future prospects for general economy? GfK’s long-running Consumer Confidence Index remained at zero in March. Two of the measures used to calculate the Index saw decreases this month, with one measure showing an increase and the remaining two measures staying the same. Joe Staton, Head of Market Dynamics...